Washington, DC (PRWEB) August 12, 2009
Cardiocore, a premier centralized cardiac testing lab, announced today that it has been selected as a preferred provider by another Top-Ten pharmaceutical company. As part of its selection process, this drug developer analyzed detailed information from the leading core labs in the United States and Europe. Factors contributing to Cardiocore's selection included its flexible data management systems, world class scientists and highly-qualified project management organization.
The pharmaceutical company research teams, based at multiple locations in Europe and the United States, are supported by Cardiocore's globally distributed offices in London, San Francisco and Bethesda. The sponsor has recently awarded Cardiocore cardiac safety service contracts including multi-year global studies, a Thorough QT study and retrospective paper ECG analyses. With a large and expanding pipeline, the sponsor anticipates additional cardiac testing outsourcing in the years ahead.
Cardiocore and the sponsor have developed a successful partnership, particularly in the areas of customized data management and statistical analyses. Inspired by collaborative process, Cardiocore Chief Medical Officer, Lawrence Satin, MD, FACC, explained, "This sponsor organization is committed to accomplishing two simultaneous goals. Not only are they doing an excellent job in developing their clinical programs, but they are also proactively contributing to the scientific advancement of cardiac safety research. Our staff is proud to participate in these valuable achievements."
Cardiocore Chief Executive Officer, Jennifer Cotteleer said, "We are very pleased to earn this preferred provider award from another one of the world's largest drug developers." She continued, "In the years to come, Cardiocore will continue to support their clinical programs including global trials and Thorough QT studies. Having established a strong collaborative relationship and successful service deliveries, we anticipate a vibrant, long-lasting partnership."
Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 17 years. Services include centralized electrocardiography (ECG), Holter monitoring, echocardiography (ECHO), multigated acquisition scans (MUGA), protocol development and statistical analysis. The company is experienced in cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company's advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore's U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England. http://www.cardiocore.com.